TY - JOUR
T1 - The Role of Carbon Ion Therapy in the Changing Oncology Landscape-A Narrative Review of the Literature and the Decade of Carbon Ion Experience at the Italian National Center for Oncological Hadrontherapy
AU - Orlandi, Ester
AU - Barcellini, Amelia
AU - Vischioni, Barbara
AU - Fiore, Maria Rosaria
AU - Vitolo, Viviana
AU - Iannalfi, Alberto
AU - Bonora, Maria
AU - Chalaszczyk, Agnieszka
AU - Ingargiola, Rossana
AU - Riva, Giulia
AU - Ronchi, Sara
AU - Valvo, Francesca
AU - Fossati, Piero
AU - Ciocca, Mario
AU - Mirandola, Alfredo
AU - Molinelli, Silvia
AU - Pella, Andrea
AU - Baroni, Guido
AU - Pullia, Marco Giuseppe
AU - Facoetti, Angelica
AU - Orecchia, Roberto
AU - Licitra, Lisa
AU - Vago, Gianluca
AU - Rossi, Sandro
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/10/20
Y1 - 2023/10/20
N2 - BACKGROUND: Currently, 13 Asian and European facilities deliver carbon ion radiotherapy (CIRT) for preclinical and clinical activity, and, to date, 55 clinical studies including CIRT for adult and paediatric solid neoplasms have been registered. The National Center for Oncological Hadrontherapy (CNAO) is the only Italian facility able to accelerate both protons and carbon ions for oncological treatment and research.METHODS: To summarise and critically evaluate state-of-the-art knowledge on the application of carbon ion radiotherapy in oncological settings, the authors conducted a literature search till December 2022 in the following electronic databases: PubMed, Web of Science, MEDLINE, Google Scholar, and Cochrane. The results of 68 studies are reported using a narrative approach, highlighting CNAO's clinical activity over the last 10 years of CIRT.RESULTS: The ballistic and radiobiological hallmarks of CIRT make it an effective option in several rare, radioresistant, and difficult-to-treat tumours. CNAO has made a significant contribution to the advancement of knowledge on CIRT delivery in selected tumour types.CONCLUSIONS: After an initial ramp-up period, CNAO has progressively honed its clinical, technical, and dosimetric skills. Growing engagement with national and international networks and research groups for complex cancers has led to increasingly targeted patient selection for CIRT and lowered barriers to facility access.
AB - BACKGROUND: Currently, 13 Asian and European facilities deliver carbon ion radiotherapy (CIRT) for preclinical and clinical activity, and, to date, 55 clinical studies including CIRT for adult and paediatric solid neoplasms have been registered. The National Center for Oncological Hadrontherapy (CNAO) is the only Italian facility able to accelerate both protons and carbon ions for oncological treatment and research.METHODS: To summarise and critically evaluate state-of-the-art knowledge on the application of carbon ion radiotherapy in oncological settings, the authors conducted a literature search till December 2022 in the following electronic databases: PubMed, Web of Science, MEDLINE, Google Scholar, and Cochrane. The results of 68 studies are reported using a narrative approach, highlighting CNAO's clinical activity over the last 10 years of CIRT.RESULTS: The ballistic and radiobiological hallmarks of CIRT make it an effective option in several rare, radioresistant, and difficult-to-treat tumours. CNAO has made a significant contribution to the advancement of knowledge on CIRT delivery in selected tumour types.CONCLUSIONS: After an initial ramp-up period, CNAO has progressively honed its clinical, technical, and dosimetric skills. Growing engagement with national and international networks and research groups for complex cancers has led to increasingly targeted patient selection for CIRT and lowered barriers to facility access.
UR - http://www.scopus.com/inward/record.url?scp=85175048021&partnerID=8YFLogxK
U2 - 10.3390/cancers15205068
DO - 10.3390/cancers15205068
M3 - Review article
C2 - 37894434
SN - 2072-6694
VL - 15
JO - Cancers
JF - Cancers
IS - 20
M1 - 5068
ER -